Literature DB >> 26231252

Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage III and IV disease.

Loredana Costa1, Sara Pedretti2, Federica Foscarini2, Marta Maddalo2, Ludovica Pegurri1, Nadia Pasinetti1, Roberta Cavagnini2, Stefano Ciccarelli2, Sandro Tonoli1, Stefano Maria Magrini1,2, Michela Buglione3,4.   

Abstract

PURPOSE: To compare toxicity, survival and laryngeal preservation rate after radiotherapy alone (RR), radiotherapy after supraglottic horizontal laryngectomy (SHLR) and radiotherapy after total laryngectomy (TLR) for advanced supraglottic laryngeal cancer.
MATERIALS AND METHODS: From 1984 to 2012, 532 patients (pts) were treated in our Department: 273 were potentially fit for conservative surgery (Group I) and 259 were not amenable to partial surgery (Group II).
RESULTS: A younger age (p = 0.005), a better performance status (p < 0.001), the absence of comorbidities (p < 0.001) and the absence of nodal involvement (p = 0.006) favorably impacted on overall survival. More high-grade mucositis (p = 0.009), mild dysphagia (p < 0.001) and mild xerostomia (p < 0.001) were found in RR group; surgical patients had more edema of neck (p = 0.009) and skin toxicity (p = 0.008). Group I No differences in local, nodal and distant recurrences and in number of rescue laryngectomies were observed. The disease characteristics (T, N and stage) but not the treatment modality impacted on disease-free survival (DFS). Group II There was an higher number of local (p = 0.013) and nodal (p = 0.022) recurrences after RR. DFS (p = 0.01) was longer after TLR. No differences in DFS between TLR patients and RR patients who underwent radio-chemotherapy were found.
CONCLUSION: In Group I, RR results in a local-regional control and organ preservation comparable to surgical treatments, with only slight increase of late mild xerostomia and dysphagia. In Group II RR was less effective than TLR, with a significantly worse DFS. The use of concurrent radical radio-chemotherapy seems to provide comparable loco-regional control to TLR.

Entities:  

Keywords:  Laryngeal preservation; Radiotherapy; Supraglottic larynx cancer; Survival; Toxicity

Mesh:

Year:  2015        PMID: 26231252     DOI: 10.1007/s11547-015-0565-6

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  31 in total

1.  Oncologic outcomes after supracricoid partial laryngectomy.

Authors:  Isabel Sánchez-Cuadrado; Alejandro Castro; Ricardo Bernáldez; Antonio Del Palacio; Javier Gavilán
Journal:  Otolaryngol Head Neck Surg       Date:  2011-03-01       Impact factor: 3.497

2.  Supracricoid partial laryngectomies: oncologic and functional results.

Authors:  M de Vincentiis; A Minni; A Gallo; A Di Nardo
Journal:  Head Neck       Date:  1998-09       Impact factor: 3.147

Review 3.  Systematic review of dose--volume correlates for structures related to late swallowing disturbances after radiotherapy for head and neck cancer.

Authors:  Fréderic Duprez; Indira Madani; Bruno De Potter; Tom Boterberg; Wilfried De Neve
Journal:  Dysphagia       Date:  2013-02-22       Impact factor: 3.438

Review 4.  [The current role of partial surgery as a strategy for functional preservation in laryngeal carcinoma].

Authors:  Juan Pablo Rodrigo; Andrés Coca-Pelaz; Carlos Suárez
Journal:  Acta Otorrinolaringol Esp       Date:  2010-08-03

5.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

6.  Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues.

Authors:  Nam P Nguyen; Sabah Sallah; Ulf Karlsson; John E Antoine
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

7.  Supracricoid partial laryngectomy in the management of t3 laryngeal cancer.

Authors:  Giuseppe Mercante; Alberto Grammatica; Paolo Battaglia; Giovanni Cristalli; Raul Pellini; Giuseppe Spriano
Journal:  Otolaryngol Head Neck Surg       Date:  2013-08-06       Impact factor: 3.497

8.  Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.

Authors:  Jimmy J Caudell; Philip E Schaner; Ruby F Meredith; Julie L Locher; Lisle M Nabell; William R Carroll; J Scott Magnuson; Sharon A Spencer; James A Bonner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-07-16       Impact factor: 7.038

9.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

10.  Transoral laser microsurgery for advanced laryngeal cancer.

Authors:  Michael L Hinni; John R Salassa; David G Grant; Bruce W Pearson; Richard E Hayden; Alexios Martin; Hans Christiansen; Bruce H Haughey; Brian Nussenbaum; Wolfgang Steiner
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-12
View more
  1 in total

1.  Intensity-Modulated Radiotherapy (IMRT) following Conservative Surgery of the Supraglottic Region: Impact on Functional Outcomes.

Authors:  Daniela Alterio; Simona Marani; Valeria Zurlo; Stefano Filippo Zorzi; Annamaria Ferrari; Stefania Volpe; Francesco Bandi; Sabrina Vigorito; Maria Giulia Vincini; Sara Gandini; Aurora Gaeta; Cristiana Iuliana Fodor; Alessia Casbarra; Mattia Zaffaroni; Anna Starzyńska; Liliana Belgioia; Mohssen Ansarin; Cynthia Aristei; Barbara Alicja Jereczek-Fossa
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.